First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Amgen
Amgen
Debiopharm International SA
Boehringer Ingelheim
Boehringer Ingelheim
Merck Sharp & Dohme LLC
BeiGene
RayzeBio, Inc.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
EMD Serono
Servier
AstraZeneca
Genentech, Inc.
Bristol-Myers Squibb
Celgene
Akeso
BeBetter Med Inc
Innovent Biologics (Suzhou) Co. Ltd.
Hoffmann-La Roche
EMD Serono
Lumos Pharma
EMD Serono
AbbVie
Bristol-Myers Squibb
Gilead Sciences
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Sanofi
AstraZeneca
GlaxoSmithKline